Form D · Biotechnology
NOVAI LTD
Reading, X0 · CIK 0001968417
Offering snapshot reported May 15, 2023 · SEC filing
- Reported sold
- $1.13M Offering amount: $1.13M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 30, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 15, 2023 | Initial | $1,131,702 | No comparison | 22 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-481658
THE TOTAL INVESTMENT FOR THIS ROUND WAS $1131702.31 WITH ONLY ONE U.S. INVESTOR WHICH SUBSCRIBED $249973.33. THIS FORM D IS USING THE BANK OF ENGLAND EXCHANGE RATE ON 17 APRIL 2023.
Source: Form D, filed May 15, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Maria Francesca Cordeiro | Director |
| Karl David Keegan | Director |
| Stephen Roy Page | Director |
| Natalie Pankova | Director |
| James Hedley Rawlingson | Director |
| Christopher Mark Wheatcroft | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
The White Building, Worklife 33 King's Road
Reading, X0, RG1 3AR
Reading, X0, RG1 3AR